ACS’s Siegel: Large drop in lung cancer mortality likely driven by treatment, not just drugs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Rebecca Siegel doesn’t usually pay attention to one-year drops in data trends, but the 2.2% decline in overall cancer mortality from 2016 to 2017—driven primarily by lung cancer—seemed too big to ignore.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login